Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir combination in non-cirrhotic genotype 1 HCV
NCT03020082Phase 3Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of danoprevir in hepatitis C (HCV), sponsored by Ascletis Pharma Inc.. Started Jun 2016; status: completed.
02
Drugs
danoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03020082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020082.